Clinical Trial: Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients

U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07695090) titled 'Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients' on May 05, 2025.

Brief Summary: Cognitive impairment (CI) is highly prevalent in patients with heart failure with reduced ejection fraction (HFrEF), which has significant implications for disease management, quality of life and clinical outcomes. Currently, there are no specific treatments for CI aside from the current standard of care therapy for HF, making this a high unmet medical need. Impaired cerebral autoregulation is a proposed mechanistic factor that leads to cerebral hypoperfusion, ischemic damage and the development for CI. Preclinical d...